Summary of the Conference Call Company Overview - The conference call featured Qiu Hong, the Secretary of the Board and CFO of Jianhui Information, discussing the recent operational status of the company [1] Key Points and Arguments - Qiu Hong expressed gratitude for the opportunity to share updates with investors and highlighted the company's recent operational performance [1] Additional Important Content - The call included a Q&A session to address investor inquiries, indicating a focus on transparency and engagement with stakeholders [1]

中国上海石门一路 288 号兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 junhesh@junhe.com 君合律师事务所上海分所 关于上海健麾信息技术股份有限公司 2023 年年度股东大会的法律意见书 致：上海健麾信息技术股份有限公司 君合律师事务所上海分所（以下简称"本所"）接受上海健麾信息技术股份有限 公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司 股东大会规则》（以下简称"《股东大会规则》"）等法律、法规、规范性文件（以 下简称"法律、法规"）及《上海健麾信息技术股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，按照律师行业公认的业务标准、道德规范和勤勉尽责精 神，就公司 2023 年年度股东大会（以下简称"本次股东大会"）有关事宜出具本法 律意见书。 为出具本法律意见书之目的，本所委派律师（以下简称"本所律师"）对公司提 供的与本次股东大会有关的文件和事实进行了核查和验证。在本所律师对公司提 ...

证券代码：605186 证券简称：健麾信息 公告编号：2024-028 上海健麾信息技术股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (五) 公司董事、监事和董事会秘书的出席情况 1、公司在任董事 8 人，以现场或通讯方式出席 8 人； 2、公司在任监事 3 人，以现场或通讯方式出席 3 人； 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 7 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 68,485,122 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 50.3567% | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 1.本次股东大会采用现场投票和网络投票相结合的表决方式； 2.本次股东大会由公司董事会召集，现场会议由公司董事长戴建伟先生主持； 3.本次股东大会的召集和召开程序以及表决方式和 ...

上海健麾信息技术股份有限公司 2023年年度股东大会会议资料 证券代码：605186 证券简称：健麾信息 上海健麾信息技术股份有限公司 Shanghai General Healthy Information and Technology Co., Ltd. 2023 年年度股东大会 会议资料 中国•上海 二〇二四年六月二十七日 上海健麾信息技术股份有限公司 2023年年度股东大会会议资料 目录 | 2023 | | 年年度股东大会会议须知 1 | | | --- | --- | --- | --- | | 2023 | | 年年度股东大会会议议程 3 | | | | 议案一：关于《2023 | 年度董事会工作报告》的议案 5 | | | | 议案二：关于《2023 | 年度监事会工作报告》的议案 6 | | | | 议案三：关于《2023 | 年度财务决算及 2024 年度财务预算报告》的议案 | 7 | | | 议案四：关于《2023 | 年度利润分配方案》的议案 8 | | | | 议案五：关于《2023 | 年年度报告》及其摘要的议案 13 | | | | 议案六：关于《续聘 | 2024 年度会计师 ...

Group 1: Market Performance and Technical Advantages - The company is recognized as a leading provider of pharmaceutical logistics automation, information technology, and mobile healthcare solutions, with significant advantages in software and hardware system integration, data processing, equipment management, automated dispensing, and robotics technology [1] - The company plans to enhance R&D investment to meet the growing demands of the overseas market and drive product innovation and technological upgrades [1] Group 2: Dividend Policy and Shareholder Returns - For the fiscal year 2023, the company plans to distribute a cash dividend of 1.00 yuan (tax included) for every 10 shares, totaling 13,600,000.00 yuan (tax included), which represents 22.67% of the net profit attributable to shareholders [2] - The company aims to establish a robust shareholder return mechanism to protect the rights of minority shareholders and create stable return expectations [2] Group 3: Industry Policy Trends - The healthcare sector is experiencing significant impacts from policy reforms, with a focus on promoting high-quality development in public hospitals, which is expected to enhance market conditions [2] - The company will actively respond to the policy environment, adjust its business strategies, strengthen product R&D, expand overseas markets, and optimize production and management efficiency [2]

证券代码：605186 证券简称：健麾信息 公告编号：2024-027 上海健麾信息技术股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2023 年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开的日期、时间和地点 召开的日期时间：2024 年 6 月 27 日 13 点 30 分 召开地点：上海市松江区中辰路 518 号 A 栋会议室 (五)网络投票的系统、起止日期和投票时间。 股东大会召开日期：2024年6月27日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (七)涉及公开征集股东投票权 不涉及 二、 会议审议事项 本次股东大 ...

证券代码：605186 证券简称：健麾信息 公告编号：2024-026 上海健麾信息技术股份有限公司 关于召开 2023 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 说明会类型 会议召开时间：2024 年 06 月 13 日(星期四) 下午 15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 06 月 05 日(星期三) 至 06 月 12 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 stock@g-healthy.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2023 年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 06 月 13 日 下午 15 ...

证券简称：健麾信息 证券代码：605186 公告编号：2024-025 交易标的：美团买药现有运营的智慧零售项目资产。 成交金额：13,506,000元人民币 本次购买资产事项无需公司董事会及股东大会审议。 上海健麾信息技术股份有限公司 关于签署"智慧药店"战略合作协议的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带 责任。 重要内容提示： 2024年2月9日，上海健麾信息技术股份有限公司（以下简称"公司"、 "甲方"、"健麾信息"）与北京三快在线科技有限公司（以下简称"乙 方"、"三快在线"或"美团买药"）签署了《关于"智慧药店"之战略 合作协议》。基于前述战略合作协议约定，双方签署了《关于"智慧零售 项目"业务收购协议》。近日，双方就上述交易事项，已完成资产交割程 序。 本次购买资产事项不构成关联交易，也不构成《上市公司重大资产重组 管理办法》规定的重大资产重组，交易实施不存在重大法律障碍。 一、合同签署情况 2024年2月9日，健麾信息与美团买药双方签署了《关于"智慧药店"之战略合 作协议》。具体内容详见公司于 ...

Revenue and Profitability - Revenue for Q1 2024 was CNY 35,633,143.76, a decrease of 41.85% compared to the same period last year[5] - Net profit attributable to shareholders was CNY 5,242,315.57, down 47.28% year-over-year[11] - Basic earnings per share decreased by 42.86% to CNY 0.04[6] - Total operating revenue for Q1 2024 was ¥35,633,143.76, a decrease of 41.9% compared to ¥61,275,234.89 in Q1 2023[20] - Net profit for Q1 2024 was ¥2,357,351.02, a decline of 71.5% from ¥8,258,699.04 in Q1 2023[21] - The company’s total comprehensive income for Q1 2024 was ¥2,357,351.02, significantly lower than ¥8,258,699.04 in Q1 2023[22] Cash Flow and Liquidity - Operating cash flow was negative at CNY -64,638,160.26, indicating cash outflow from operations[5] - Cash flow from operating activities for Q1 2024 was -¥64,638,160.26, worsening from -¥46,915,420.31 in Q1 2023[26] - Cash received from sales and services in Q1 2024 was ¥48,022,274.36, down from ¥65,772,336.09 in Q1 2023[25] - Total cash inflow from financing activities was $18.5 million, compared to $25 million in the previous period, reflecting a decrease of 26%[27] - Net cash flow from financing activities was $7.94 million, down from $24.74 million, indicating a decline of approximately 68%[27] - The beginning cash and cash equivalents balance was $233.7 million, down from $334.1 million, representing a decline of 30%[27] - The ending cash and cash equivalents balance stood at $153.16 million, significantly lower than the previous period's $270.99 million[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,314,232,411.33, a slight decrease of 0.19% from the previous year[6] - As of March 31, 2024, the total assets amounted to CNY 1,314,232,411.33, a slight decrease from CNY 1,316,771,113.76 as of December 31, 2023[16] - The total current assets decreased to CNY 747,895,826.33 from CNY 771,442,780.41, reflecting a decline of approximately 3.03%[17] - Total liabilities decreased to CNY 174,161,640.21 from CNY 179,057,693.66, a decline of approximately 2.5%[18] - Current liabilities totaled CNY 171,879,896.10, down from CNY 176,743,449.55, reflecting a decrease of about 2.7%[18] - The company's long-term investments in equity decreased to CNY 103,196,368.37 from CNY 106,264,662.39, a decline of approximately 2.9%[17] Expenses and Costs - Sales expenses increased by 59.93% due to higher marketing and exhibition costs compared to the previous year[10] - Total operating costs for Q1 2024 were ¥34,358,791.33, down 33.9% from ¥51,831,889.26 in Q1 2023[20] - Research and development expenses increased to ¥6,600,012.24 in Q1 2024, compared to ¥5,567,972.60 in Q1 2023[20] Investment and Financing - The company faced a 438.17% decrease in investment income, impacted by market fluctuations due to industry policy reforms[10] - The company reported an investment loss of ¥3,068,294.00 in Q1 2024, compared to a gain of ¥907,316.23 in Q1 2023[20] - The impact of exchange rate changes on cash and cash equivalents was a negative $216,890.98, contrasting with a positive impact of $24,162.34 in the previous period[27] Other Financial Metrics - The weighted average return on equity decreased by 0.48 percentage points to 0.50%[6] - Cash and cash equivalents were reported at CNY 194,841,705.34, down from CNY 267,759,758.00, indicating a decrease of about 27.2%[16] - Accounts receivable slightly decreased to CNY 372,893,082.73 from CNY 384,328,926.60, a reduction of approximately 2.5%[16] - Inventory increased to CNY 81,443,064.78 from CNY 65,155,346.70, representing an increase of about 24.9%[17] - The company reported a significant increase in other receivables, rising to CNY 15,037,067.20 from CNY 10,542,533.71, an increase of approximately 42.5%[17]

Financial Performance - The net profit attributable to the parent company's shareholders for 2023 is CNY 59,999,960.99, with a distributable profit of CNY 245,379,674.89 as of December 31, 2023[6]. - The proposed cash dividend is CNY 1.00 per 10 shares (including tax), totaling CNY 13,600,000, which accounts for 22.67% of the annual net profit attributable to the parent company[6]. - In 2023, the company's operating revenue was CNY 307,559,138.41, a decrease of 4.59% compared to CNY 322,359,785.92 in 2022[23]. - The net profit attributable to shareholders was CNY 59,999,960.99, down 48.13% from CNY 115,681,544.43 in the previous year[23]. - The basic earnings per share decreased to CNY 0.44, a decline of 48.24% from CNY 0.85 in 2022[24]. - The total assets at the end of 2023 were CNY 1,316,771,113.76, reflecting a 9.84% increase from CNY 1,198,844,121.40 in 2022[23]. - The weighted average return on equity was 5.82%, down 6.29 percentage points from 12.11% in 2022[24]. - The cash flow from operating activities showed a net outflow of CNY 35,393,790.08, compared to an inflow of CNY 53,827,755.74 in 2021[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 45,204,051.03, a decrease of 53.27% from CNY 96,730,991.02 in 2022[23]. - The company reported a net asset attributable to shareholders of CNY 1,052,726,420.24 at the end of 2023, an increase of 4.75% from CNY 1,004,966,459.25 in 2022[23]. Risk Management - The report includes a risk statement regarding forward-looking statements, emphasizing that future plans and strategies do not constitute a commitment to investors[7]. - The management discussion and analysis section outlines potential risks that investors should pay attention to[9]. - The company experienced a significant impact on performance due to a slowdown in global economic growth and weakened domestic market demand[23]. - The overall market environment remains challenging, with no significant changes in the industry during the reporting period[40]. - The company recognizes the risk of dependency on its subsidiary Willach for core components of its H series automated dispensing machines, which could impact operations if the partnership deteriorates[126]. - The company faces risks related to customer and supplier concentration, which could adversely affect its profitability if relationships change significantly[128][130]. Strategic Initiatives - The company plans to adapt to the changing market conditions and explore new strategies to enhance performance in the upcoming periods[23]. - The company established a joint venture in Riyadh, Saudi Arabia, with Ajlan & Bros Information Technology Company to promote its products in the Middle East and North Africa, with the first project already operational in a leading private hospital[34]. - The company is strategically expanding into the pharmaceutical retail market by partnering with industry leaders and implementing a "smart pharmacy" model, aiming for nationwide replication[36]. - Increased R&D investment is being directed towards product innovation and technology upgrades to enhance competitiveness in international markets[37]. - The company is actively exploring digital transformation projects in collaboration with the Saudi Ministry of Health, targeting over 2,300 primary healthcare centers[34]. - The company aims to integrate its "smart pharmacy" model with beauty and personal care products, expanding its offerings beyond pharmaceuticals[36]. - The company is focusing on expanding its market through external investments, as indicated by the increase in cash flow from financing activities[70]. Research and Development - The company emphasizes the importance of research and development to maintain its competitive edge in the market[54]. - The company has a well-established R&D system with nearly 20 years of experience in intelligent drug management projects, indicating strong technical innovation capabilities[61]. - Research and development expenses increased by 4.25% to 23.37 million yuan, reflecting the company's commitment to innovation[68]. - The company plans to enhance its R&D capabilities and product development, focusing on machine vision, deep learning, and robotics to lead market demand and achieve innovation[119]. Corporate Governance - The company has established specialized committees under the board to ensure scientific and standardized decision-making[136]. - The company maintains independence from its controlling shareholder in terms of assets, personnel, finance, and operations[139]. - The total remuneration for the board members and senior management during the reporting period amounted to CNY 6,665,289.24[143]. - The company emphasizes investor relations management through various channels to enhance communication and protect investor rights[138]. - The company has not faced any penalties from securities regulatory authorities in the past three years[153]. Shareholder Commitments - The controlling shareholder and actual controller, Dai Jianwei, committed to not transferring or entrusting the management of shares held before the issuance for 36 months after the company's stock listing[187]. - The company will ensure compliance with regulations regarding shareholding changes and lock-up periods during the tenure of its directors and senior management[190]. - The commitments made by shareholders and controllers are designed to stabilize the stock price post-IPO and ensure long-term investment[187]. - The company will implement stock price stabilization measures if the stock price falls below the audited net asset value per share for 20 consecutive trading days[198]. Market Expansion - The company is focusing on expanding its investment in the medical and healthcare sectors, indicating a strategic shift towards high-growth industries[108]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[148]. - The company aims to enhance its software and hardware integration services, particularly in the field of hospital logistics and automation systems[112]. - The company plans to enhance the overall hospital market environment through the promotion of high-quality public hospital development and improved public health service capabilities[46]. Financial Health - Cash and cash equivalents at the end of the period decreased by 26.90% to ¥267,759,758, compared to ¥366,273,999.90 at the end of the previous period[86]. - Accounts receivable increased by 15.45% to ¥384,328,926.60, up from ¥332,887,498.88 in the previous period[87]. - Long-term equity investments rose significantly by 129.57% to ¥106,264,662.39, compared to ¥46,287,612.06 at the end of the previous period[87]. - The company’s total non-current financial assets reached RMB 55.6 million, with a significant increase in fair value[106]. Employee Management - The total number of employees in the parent company and major subsidiaries is 355, with 31 in the parent company and 324 in subsidiaries[164]. - Employee composition includes 62 production personnel, 50 sales personnel, 70 technical personnel, 8 financial personnel, 12 administrative personnel, 27 management personnel, and 126 operational personnel[164]. - The company emphasizes talent development through a structured training program, which includes onboarding, professional skills training, sales training, and management training[167].